Monoclonal antibody · Kills target cells, directed at B7-H3 (CD276) · developed by MacroGenics
Enoblituzumab is a humanized monoclonal antibody with an Fc domain optimized for effector function, directed against cancer stem cells and differentiated tumor cells. It binds B7-H3, a protein expressed on tumor cells, and may induce antibody-dependent cell-mediated cytotoxicity against these cells. It is studied in prostate cancer, melanoma, head and neck cancer, non-small cell lung cancer and urothelial carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06014255 | Phase 2 | Prostate Cancer | Active not recruiting | MGNX |
| NCT02475213 | Phase 1 | Melanoma | Completed | MGNX |
| NCT01918930 | Phase 1 | Melanoma | Terminated | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Prostate CancerHead and Neck CancerMelanomaNon Small Cell Lung CancerUrothelial Carcinoma
Updated Nov 22, 2026. Something wrong or missing? Report it on the MGNX page.
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →